Delpacibart etedesiran
RNA / oligonucleotide
Also known as EWF980, AOC 1001
Evidence outlook · registrational
Myotonic Dystrophy Type 1: topline reported 2026-09-08
Its supporting mid-stage studies have completed. The sponsor reported topline results on 2026-09-08 (Phase III HARBOR misses primary endpoint of vHOT). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other DMPK drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Myotonic Dystrophy Type 1: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Delpacibart Etedesiran: this drug | Phase 3 | RNA / oligonucleotide | DMPK | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Phase 2 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-670 | Phase 2 | RNA / oligonucleotide | DMPK CUG-repeat RNA | not yet graded | No reviewed efficacy summary in this indication | |
| SAR446268 | Phase 1/2 | Gene therapy / editing | DMPK | not yet graded | No reviewed efficacy summary in this indication | |
| SRP-1003 | Phase 1/2(overall) | RNA / oligonucleotide | DMPK (dystrophia myotonica protein kinase) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Delpacibart etedesiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
October 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent